Otros idiomas Design Therapeutics, Inc.

Acciones

DSGN

US25056L1035

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 28/06/2024			Varia. Cinco días.	Varia. 1 de enero.
3,35 ^USD	0,00 %		-0,89 %	+26,42 %

17/06	Design Therapeutics, Inc. Elige a Pratik Shah, Ph.D. como Director de Clase III	CI
08/05	Design Therapeutics, Inc. presenta los resultados del primer trimestre finalizado el 31 de marzo de 2024	CI

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

Design Therapeutics, Inc. Elects Pratik Shah, Ph.D. as Class III Director	17/06
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones	08/05
Design Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference	07/05
Sector Update: Health Care Stocks Ease Late Afternoon	20/03
Sector Update: Health Care Stocks Down Wednesday Afternoon	20/03
Design Therapeutics Stock Rises as RBC Says Q4 Results, Product Candidate Updates Show Progress	20/03
Design Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results	19/03
Design Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	19/03
North American Morning Briefing : Stock Futures -2-	19/03
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update	12/03
Design Therapeutics, Inc.(NasdaqGS:DSGN) dropped from NASDAQ Biotechnology Index	15/12
Design Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024	13/11
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN	10/10/23
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN	30/09/23
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN	22/09/23
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN	14/09/23
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN	06/09/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Design Therapeutics, Inc.

Acciones

DSGN

US25056L1035

Otros idiomas

Filtros